SCHEMBL24137922

SCHEMBL24137922

C[C@H](Nc1cncc(-c2cccc(NC(=O)CCc3ccccc3)c2)c1)c1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 2/20 0.54
▸ MAPT P10636 2/20 0.54
▸ HTR7 P34969 2/20 0.54
▸ LMNA P02545 2/20 0.52
▸ CDK8 P49336 1/20 0.52
▸ MMP2 P08253 3/20 0.49
▸ MMP9 P14780 3/20 0.49
▸ MMP8 P22894 3/20 0.49
▸ RAB9A P51151 2/20 0.49
▸ ALDH1A1 P00352 2/20 0.49
▸ ALOX15 P16050 1/20 0.49
▸ SENP1 Q9P0U3 1/20 0.48
▸ HPGD P15428 2/20 0.48
▸ HTT P42858 1/20 0.48
▸ MMP3 P08254 1/20 0.48
▸ KDM4E B2RXH2 1/20 0.47
▸ MEN1 O00255 1/20 0.47
▸ TSHR P16473 1/20 0.47
▸ MAPK1 P28482 1/20 0.47
▸ KMT2A Q03164 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24137863 0.86 CDK7 (0.46) MAPTHTR7ALDH1A1HPGDHTT
SCHEMBL24137867 0.85 HTR7 (0.47) MAPTHTR7LMNACDK8RAB9A
SCHEMBL24137860 0.81 KMT2A (0.52) GAAMAPTALDH1A1HPGDKDM4E
SCHEMBL24137805 0.77 HTR7 (0.60) GAAHTR7CDK8KDM4E
SCHEMBL25937910 0.75 HTR7 (0.51) GAAHTR7KDM4E
SCHEMBL24137550 0.74 HTR7 (0.50) GAAHTR7CDK8KDM4EMEN1
SCHEMBL24137533 0.72 CSF1R (0.49) MAPTHTR7HTTKDM4EMEN1
SCHEMBL5888147 0.72 PRCP (0.54) LMNARAB9AALDH1A1KMT2ASMN1; SMN2
SCHEMBL5888153 0.72 PRCP (0.54) LMNARAB9AALDH1A1KMT2ASMN1; SMN2
SCHEMBL29079351 0.71 MAPT (0.68) GAAMAPTMMP2MMP9MMP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230234935-A1 KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 2023-07-27 — — US disclosed
WO-2021263129-A1 KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2021-12-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230234935-A1 KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE PACSIN2, MAP3K20, PHKG1 GAA 631/4885MAPT 1315/4885HTR7 2493/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback